Delivery of maternal health care in Indigenous primary care services: baseline data for an ongoing quality improvement initiative

Table 4 Delivery of laboratory and ultrasound investigations

Service item	NT Top End	NT Central Australia	Far West NSW	WA	North QLD	Total
No. of health centres \| client records	13 \| 136	2 \| 45	6 \| 103	9 \| 193	4 \| 58	34 \| 535
First antenatal assessment
Blood group/Rhesus	96%	100%	65%	77%	79%	82%*
Antibodies	93%	100%	66%	70%	78%	79%*
MSU	91%	96%	40%	67%	76%	71%*
FBE	95%	100%	64%	73%	79%	80%*
Rubella	92%	100%	61%	70%	78%	77%*
HBsAg	91%	100%	56%	75%	79%	78%*
Syphilis serology	94%	100%	58%	55%	81%	72%*
HIV	80%	89%	14%	72%	59%	63%*
Offered fetal anomaly screening	6%	33%	17%	20%	0%	15%*
Fetal anomaly screening
Client agreed to fetal anomaly screening	3%	18%	18%	15%	0%	11%*
Nuchal translucency	0%	13%	6%	3%	0%	3%*
First trimester combined screen	0%	11%	10%	3%	2%	4%*
Maternal serum screening 14-20 weeks	2%	2%	17%	8%	2%	7%*
Investigations between 20 and 28 weeks
50 or 70 g glucose challenge test or glucose tolerance test	78%	49%	33%	38%	66%	51%*
FBE	82%	69%	24%	46%	60%	54%*
Investigation between 34 and 37 weeks
Low vaginal swab for GBS	49%	62%	31%	29%	10%	35%*
Routine ultrasound check
Before 16 weeks	32%	49%	38%	39%	24%	36%
16-20 weeks	47%	69%	31%	41%	34%	42%

FBE = full blood examination, GBS = group B streptococcus, HBsAg = hepatitis B antigen, HIV = human immunodeficiency virus, MSU = midstream urine.
* P < 0.05 for comparisons between regions.

ISSN: 1471-2393